Poor
Not Aligned
Patient Risk:
Moderate
Summary
Substantial portions of the extracted claims are not supported by the provided FDA label excerpts (frequently marked as absent), including multiple dosing generalizations, tablet-specific appearance/score-line, brand naming, mechanistic detail, and adverse-effect frequency/severity. Only a few mechanism/administration points align with the provided label text.
Category Scores
Accurate Statements
Tizanidine works by acting on the central nervous system.
Supported by provided label section 12.1 Mechanism of Action (central alpha-2-adrenergic receptor agonist).
Tizanidine stimulates alpha-2 adrenergic receptors.
Supported by provided label sections 11 DESCRIPTION and 12.1 Mechanism of Action (alpha-2-adrenergic agonist).
Tizanidine is taken by mouth.
Supported by provided label section 3 DOSAGE FORMS AND STRENGTHS (oral solution).
Unsupported Statements
Tizanidine 4 mg tablets are typically small, round, and white or off-white in color.
Tablet-specific appearance is not supported by the provided label excerpts; marked absent in the supplied evaluation.
Tizanidine 4 mg tablets may have a score line on one side indicating they can be split.
No tablet/score-line information is present in the provided label excerpts; marked absent.
Tizanidine is available under the brand name Zanaflex in the United States.
Zanaflex branding is not supported by provided label excerpts; marked absent.
Spasticity is a condition of increased muscle stiffness and frequent muscle spasms.
No spasticity definition is provided in the supplied label excerpts; marked absent.
Tizanidine is commonly prescribed for conditions such as multiple sclerosis.
The provided label excerpt states indication for spasticity in adults but does not list or support MS as a specifically cited common indication; marked absent.
Tizanidine is commonly prescribed for conditions such as spinal cord injury.
Not supported by provided label excerpts; marked absent.
Tizanidine is commonly prescribed for conditions such as stroke.
Not supported by provided label excerpts; marked absent.
Tizanidine specifically acts at alpha-2 adrenergic receptor sites in the brain and spinal cord.
Mechanism is described generally as central alpha-2-adrenergic receptor agonist; brain/spinal cord localization is not clearly supported by the provided excerpts as stated; marked partially supported/uncertain in supplied evaluation.
By stimulating alpha-2 adrenergic receptors, tizanidine inhibits the release of excitatory neurotransmitters that contribute to muscle spasms and spasticity.
This mechanistic detail is not supported by the provided label excerpts; marked absent.
Common side effects associated with tizanidine include drowsiness.
Adverse reactions are referenced but specific 'common side effects' (including drowsiness) are not supported by the provided label excerpts; marked absent.
Common side effects associated with tizanidine include dizziness.
Not supported by provided label excerpts; marked absent.
Common side effects associated with tizanidine include dry mouth.
Not supported by provided label excerpts; marked absent.
Common side effects associated with tizanidine include fatigue.
Not supported by provided label excerpts; marked absent.
Common side effects associated with tizanidine include weakness.
Not supported by provided label excerpts; marked absent.
Tizanidine is typically prescribed in dosages of 2 mg or 4 mg per dose.
The provided label excerpt mentions oral solution strength (2 mg/5 mL) but does not support 'typically prescribed' or 2 mg/4 mg per dose in the way claimed; marked absent.
The maximum daily dose of tizanidine is usually 36 mg.
No maximum daily dose statement appears in the provided label excerpts; marked absent.
Tizanidine dosages are adjusted based on individual response and tolerance under the guidance of a healthcare professional.
The provided label excerpt includes dose titration and monitoring around hypotension, but the specific 'individual response and tolerance' wording is not supported in the provided excerpts; marked absent.
Generic versions of tizanidine can be manufactured and marketed once patents expire and any regulatory exclusivity periods end.
Not a labeling-supported statement and no label citation is provided (N/A); marked unsupported.
Generic versions of tizanidine are required to be bioequivalent to the brand-name drug.
Not supported by provided label excerpts; no label citation (N/A); marked unsupported.
Contradictions
Important Omissions
No claims addressed formal contraindications, boxed warnings, detailed warnings/precautions, or drug interactions despite their presence in the provided label excerpt structure (e.g., strong CYP1A2 inhibitor contraindication for hypotension risk).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or incorrectly generalized dosing and adverse-effect frequency/severity could lead to inaccurate understanding of safe use. Additionally, contraindication/interaction-related safety information was not addressed in the claims, limiting alignment with label safety requirements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts (often marked absent), especially brand/tablet appearance, spasticity definition, mechanistic detail, dosing (typical dose and maximum daily dose), and adverse-effect frequency/severity.
Suggested Improvement
Restrict claims to statements directly supported by the provided label text (e.g., central alpha-2-adrenergic agonist mechanism and oral route). Remove tablet-specific and brand-specific assertions unless present in the label excerpts. Replace dosing/general frequency language with label-supported dosing/maximum/precaution details, and include label safety elements (contraindications/warnings/interactions) when evaluating safety.